miRNAs: Early prognostic biomarkers for Type 2 diabetes mellitus?

Biomarkers in Medicine

Volumn 9, Issue 10, 2015, Pages 1025-1040

  Bhatia, Parnika ^a   Raina, Shikha ^a   Chugh, Jeetender ^b   Sharma, Shilpy ^a  

^a UNIVERSITY OF PUNE   (India)

^b INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

biomarker; HbA1C; miRNA; pancreatic cell; Type 2 diabetes mellitus

Indexed keywords

BIOLOGICAL MARKER; INSULIN; MICRORNA; MICRORNA 101; MICRORNA 126; MICRORNA 130B 3P; MICRORNA 144; MICRORNA 146A; MICRORNA 150; MICRORNA 155; MICRORNA 15A; MICRORNA 182; MICRORNA 186; MICRORNA 192; MICRORNA 223; MICRORNA 23A; MICRORNA 27A; MICRORNA 29A; MICRORNA 29B; MICRORNA 30D; MICRORNA 320A; MICRORNA 34A; MICRORNA 375; MICRORNA 423 5P; MICRORNA 503; MICRORNA 802; MICRORNA 9; MICRORNA 96; MICRORNA LET 7I; UNCLASSIFIED DRUG;

BIOGENESIS; CLINICAL FEATURE; DISEASE MARKER; DISEASE PREDISPOSITION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; RNA SEQUENCE; RNA SYNTHESIS; RNA TRANSCRIPTION; TCF7L2 GENE; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION; GENETICS;

ANIMALS; BIOMARKERS; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS; PROGNOSIS;

EID: 84945284931     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.69     Document Type: Review

References (116)

1. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 32(Suppl. 1), S62-S67 (2009
2. Kumar M, Nath S, Prasad HK, Sharma GD, Li Y. MicroRNAs: a new ray of hope for diabetes mellitus. Protein Cell. 3(10), 726-738 (2012
3. Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys. Ther. 88(11), 1322-1335 (2008
4. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of Type 2 diabetes mellitus: present and future perspectives. Nat. Rev. Endocrinol. 8(4), 228-236 (2012
5. Chan RS, Woo J. Prevention of overweight and obesity: how effective is the current public health approach. Int. J. Environ. Res. Public Health. 7(3), 765-783 (2010
6. Stumvoll M, Goldstein BJ, Van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 365(9467), 1333-1346 (2005
7. International Expert C. International expert committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 32(7), 1327-1334 (2009
8. Schulze MB, Weikert C, Pischon T, et al. Use of multiple metabolic and genetic markers to improve the prediction of Type 2 diabetes: the EPIC-Potsdam study. Diabetes Care. 32(11), 2116-2119 (2009
9. Othman A, Saely CH, Muendlein A, et al. Plasma 1-deoxysphingolipids are predictive biomarkers for Type 2 diabetes mellitus. BMJ Open Diabetes Res. Care. 3(1), e000073 (2015
10. Kolberg JA, Jorgensen T, Gerwien RW, et al. Development of a Type 2 diabetes risk model from a panel of serum biomarkers from the inter99 cohort. Diabetes Care. 32(7), 1207-1212 (2009
11. Herder C, Kowall B, Tabak AG, Rathmann W. The potential of novel biomarkers to improve risk prediction of Type 2 diabetes. Diabetologia. 57(1), 16-29 (2014
12. Vinagre I, Sanchez-Quesada JL, Sanchez-Hernandez J, et al. Inflammatory biomarkers in Type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype. Cardiovasc. Diabetol. 13, 34 (2014
13. Bluher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 64(1), 131-145 (2015
14. Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat. Rev. Endocrinol. 9(9), 513-521 (2013
15. Urdea M, Kolberg J, Wilber J, et al. Validation of a multimarker model for assessing risk of Type 2 diabetes from a five-year prospective study of 6784 Danish people (inter99). J. Diabetes Sci. Technol. 3(4), 748-755 (2009
16. Guttmacher AE, Porteous ME, Mcinerney JD. Educating health-care professionals about genetics and genomics. Nat. Rev. Genet. 8(2), 151-157 (2007
17. Muller G. Microvesicles/exosomes as potential novel biomarkers of metabolic diseases. Diabetes Metab. Syndr. Obes. 5, 247-282 (2012
18. Zhou Y, Park SY, Su J, et al. Tcf7l2 is a master regulator of insulin production and processing. Hum. Mol. Genet. 23(24), 6419-6431 (2014
19. Li J, Gong YP, Li CL, Lu YH, Liu Y, Shao YH. Genetic basis of Type 2 diabetes-recommendations based on meta-Analysis. Eur. Rev. Med. Pharmacol. Sci. 19(1), 138-148 (2015
20. Brunetti A, Chiefari E, Foti D. Recent advances in the molecular genetics of Type 2 diabetes mellitus. World J. Diabetes. 5(2), 128-140 (2014
21. Kato N. Insights into the genetic basis of Type 2 diabetes. J. Diabetes Investig. 4(3), 233-244 (2013
22. Ng MC, Shriner D, Chen BH, et al. Meta-Analysis of genomewide association studies in African Americans provides insights into the genetic architecture of Type 2 diabetes. PLoS Genet. 10(8), e1004517 (2014
23. Cauchi S, El Achhab Y, Choquet H, et al. Tcf7l2 is reproducibly associated with Type 2 diabetes in various ethnic groups: a global meta-Analysis. J. Mol. Med. (Berl.) 85(7), 777-782 (2007
24. Mondal AK, Das SK, Baldini G, et al. Genotype and tissuespecific effects on alternative splicing of the transcription factor 7-like 2 gene in humans. J. Clin. Endocrinol. Metab. 95(3), 1450-1457 (2010
25. Shu XO, Long J, Cai Q, et al. Identification of new genetic risk variants for Type 2 diabetes. PLoS Genet. 6(9), e1001127 (2010
26. Wheeler E, Barroso I. Genome-wide association studies and Type 2 diabetes. Brief. Funct. Genomics. 10(2), 52-60 (2011
27. Zeggini E, Scott LJ, Saxena R, et al. Meta-Analysis of genomewide association data and large-scale replication identifies additional susceptibility loci for Type 2 diabetes. Nat. Genet. 40(5), 638-645 (2008
28. Olsson AH, Volkov P, Bacos K, et al. Genome-wide associations between genetic and epigenetic variation influence mRNA expression and insulin secretion in human pancreatic islets. PLoS Genet. 10(11), e1004735 (2014
29. Li X, Yang M, Wang H, et al. Overexpression of Jazf1 protected apoe-deficient mice from atherosclerosis by inhibiting hepatic cholesterol synthesis via CREB-dependent mechanisms. Int. J. Cardiol. 177(1), 100-110 (2014
30. Simonis-Bik AM, Nijpels G, Van Haeften TW, et al. Gene variants in the novel Type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell function. Diabetes. 59(1), 293-301 (2010
31. Haney S, Zhao J, Tiwari S, Eng K, Guey LT, Tien E. RNAi screening in primary human hepatocytes of genes implicated in genome-wide association studies for roles in Type 2 diabetes identifies roles for CAMK1d and CDKAL1, among others, in hepatic glucose regulation. PLoS ONE. 8(6), e64946 (2013
32. Jonsson A, Ladenvall C, Ahluwalia TS, et al. Effects of common genetic variants associated with Type 2 diabetes and glycemic traits on alpha- And beta-cell function and insulin action in humans. Diabetes. 62(8), 2978-2983 (2013
33. Raimondo A, Rees MG, Gloyn AL. Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism. Curr. Opin. Lipidol. 26(2), 88-95 (2015
34. Chen S, Okahara F, Osaki N, Shimotoyodome A. Increased gip signaling induces adipose inflammation via a HIF-1alpha-dependent pathway and impairs insulin sensitivity in mice. Am. J. Physiol. Endocrinol. Metab. 308(5), E414-E425 (2015
35. Ghorai A, Ghosh U. MiRNA gene counts in chromosomes vary widely in a species and biogenesis of miRNA largely depends on transcription or post-Transcriptional processing of coding genes. Front. Genet. 5, 100 (2014
36. Tolle A, Ratert N, Jung K. MiRNA panels as biomarkers for bladder cancer. Biomark. Med. 8(5), 733-746 (2014
37. Price NL, Ramirez CM, Fernandez-Hernando C. Relevance of microRNA in metabolic diseases. Crit. Rev. Clin. Lab. Sci. 51(6), 305-320 (2014
38. Rokkas T, Kothonas F, Rokka A, Koukoulis G, Symvoulakis E. The role of circulating microRNAs as novel biomarkers in diagnosing colorectal cancer: a meta-Analysis. Eur. J. Gastroenterol. Hepatol. 27(7), 819-825 (2015
39. Wang F, Chen C, Wang D. Circulating microRNAs in cardiovascular diseases: from biomarkers to therapeutic targets. Front. Med. 8(4), 404-418 (2014
40. Rognoni A, Cavallino C, Lupi A, et al. Novel biomarkers in the diagnosis of acute coronary syndromes: the role of circulating miRNAs. Expert Rev. Cardiovasc. Ther. 12(9), 1119-1124 (2014
41. Dorval V, Nelson PT, Hebert SS. Circulating microRNAs in Alzheimer's disease: the search for novel biomarkers. Front. Mol. Neurosci. 6, 24 (2013
42. Lee RC, Feinbaum RL, Ambros V. The C. Elegans Heterochronic Gene lin-4 Encodes Small RNAs with Antisense Complementarity to lin-14. Cell. 75(5), 843-854 (1993
43. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 75(5), 855-862 (1993
44. Chien CH, Sun YM, Chang WC, et al. Identifying transcriptional start sites of human microRNAs based on high-Throughput sequencing data. Nucleic Acids Res. 39(21), 9345-9356 (2011
45. Godnic I, Zorc M, Jevsinek Skok D, et al. Genome-wide and species-wide in silico screening for intragenic microRNAs in human, mouse and chicken. PLoS ONE. 8(6), e65165 (2013
46. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79, 351-379 (2010
47. Da Sacco L, Masotti A. Recent insights and novel bioinformatics tools to understand the role of microRNAs binding to 5' untranslated region. Int. J. Mol. Sci. 14(1), 480-495 (2012
48. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 136(2), 215-233 (2009
49. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19(1), 92-105 (2009
50. Friedlander MR, Lizano E, Houben AJ, et al. Evidence for the biogenesis of more than 1,000 novel human microRNAs. Genome Biol. 15(4), R57 (2014
51. Tétreault N, De Guire V. MiRNAs: their discovery, biogenesis and mechanism of action. Clin. Biochem. 46(10-11), 842-845 (2013
52. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23(20), 4051-4060 (2004
53. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20(5), 515-524 (2006
54. Lynn FC, Skewes-Cox P, Kosaka Y, Mcmanus MT, Harfe BD, German MS. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes. 56(12), 2938-2945 (2007
55. Poy MN, Hausser J, Trajkovski M, et al. MiR-375 maintains normal pancreatic alpha- And beta-cell mass. Proc. Natl Acad. Sci. USA. 106(14), 5813-5818 (2009
56. King AJ. The use of animal models in diabetes research. Br. J. Pharmacol. 166(3), 877-894 (2012
57. Zhu H, Leung SW. Identification of microRNA biomarkers in Type 2 diabetes: a meta-Analysis of controlled profiling studies. Diabetologia. 58(5), 900-911 (2015
58. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101(10), 2087-2092 (2010
59. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 56(11), 1733-1741 (2010
60. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008
61. Patnaik SK, Mallick R, Yendamuri S. Detection of microRNAs in dried serum blots. Anal. Biochem. 407(1), 147-149 (2010
62. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13(4), 423-433 (2011
63. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 38(20), 7248-7259 (2010
64. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9(6), 654-659 (2007
65. Santovito D, De Nardis V, Marcantonio P, et al. Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control. J. Clin. Endocrinol. Metab. 99(9), E1681-E1685 (2014
66. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in Type 2 diabetes. Circ. Res. 107(6), 810-817 (2010
67. Zhou J, Song S, Cen J, Zhu D, Li D, Zhang Z. MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Oncol. Res. 20(5-6), 197-203 (2012
68. Dong S, Xiong W, Yuan J, Li J, Liu J, Xu X. MiRNA-146a regulates the maturation and differentiation of vascular smooth muscle cells by targeting NF-kappab expression. Mol. Med. Rep. 8(2), 407-412 (2013
69. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NFkappab-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl Acad. Sci. USA. 103(33), 12481-12486 (2006
70. Balasubramanyam M, Aravind S, Gokulakrishnan K, et al. Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol. Cell Biochem. 351 (1-2), 197-205 (2011
71. Feng B, Chen S, Mcarthur K, et al. MiR-146a-mediated extracellular matrix protein production in chronic diabetes complications. Diabetes. 60(11), 2975-2984 (2011
72. Yang Z, Chen H, Si H, et al. Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and Type 2 diabetes. Acta Diabetol. 51(5), 823-831 (2014
73. Karolina DS, Armugam A, Tavintharan S, et al. MicroRNA144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in Type 2 diabetes mellitus. PLoS ONE. 6(8), e22839 (2011
74. Rong Y, Bao W, Shan Z, et al. Increased microRNA-146a levels in plasma of patients with newly diagnosed Type 2 diabetes mellitus. PLoS ONE. 8(9), e73272 (2013
75. Kong L, Zhu J, Han W, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed Type 2 diabetes: a clinical study. Acta Diabetol. 48(1), 61-69 (2011
76. Kuhnert F, Mancuso MR, Hampton J, et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development. 135(24), 3989-3993 (2008
77. Mcclelland AD, Kantharidis P. MicroRNA in the development of diabetic complications. Clin. Sci. (Lond.)126(2), 95-110 (2014
78. Moura J, Borsheim E, Carvalho E. The role of microRNAs in diabetic complications-special emphasis on wound healing. Genes (Basel) 5(4), 926-956 (2014
79. Ortega FJ, Mercader JM, Moreno-Navarrete JM, et al. Profiling of circulating microRNAs reveals common microRNAs linked to Type 2 diabetes that change with insulin sensitization. Diabetes Care. 37(5), 1375-1383 (2014
80. Zhang T, Lv C, Li L, et al. Plasma miR-126 is a potential biomarker for early prediction of Type 2 diabetes mellitus in susceptible individuals. Biomed. Res. Int. 2013, 761617 (2013
81. Liu Y, Gao G, Yang C, et al. The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed Type 2 diabetes mellitus. Int. J. Mol. Sci. 15(6), 10567-10577 (2014
82. Esguerra JL, Mollet IG, Salunkhe VA, Wendt A, Eliasson L. Regulation of pancreatic beta cell stimulus-secretion coupling by microRNAs. Genes (Basel) 5(4), 1018-1031 (2014
83. El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, Van Obberghen E. MiR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes. 57(10), 2708-2717 (2008).
84. Higuchi C, Nakatsuka A, Eguchi J, et al. Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for Type 2 diabetes. Metabolism. 64(4), 489-497 (2015
85. Sun K, Chang X, Yin L, et al. Expression and DNA methylation status of microRNA-375 in patients with Type 2 diabetes mellitus. Mol. Med. Rep. 9(3), 967-972 (2014
86. Wang X, Sundquist J, Zoller B, et al. Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS ONE. 9(1), e86792 (2014
87. Chuang T-Y, Wu H-L, Chen C-C, et al. MicroRNA-223 expression is upregulated in insulin resistant human adipose tissue. J. Diabetes Res. 2015, 943659 (2015
88. Sun LL, Jiang BG, Li WT, Zou JJ, Shi YQ, Liu ZM. MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression. Diabetes Res. Clin. Pract. 91(1), 94-100 (2011
89. He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3t3-l1 adipocytes. Mol. Endocrinol. 21(11), 2785-2794 (2007
90. Roggli E, Gattesco S, Caille D, et al. Changes in microRNA expression contribute to pancreatic beta-cell dysfunction in prediabetic nod mice. Diabetes. 61(7), 1742-1751 (2012
91. Chen HY, Zhong X, Huang XR, et al. MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol. Ther. 22(4), 842-853 (2014
92. Plaisance V, Waeber G, Regazzi R, Abderrahmani A. Role of microRNAs in islet beta-cell compensation and failure during diabetes. J. Diabetes Res. 2014, 618652 (2014
93. Ramachandran D, Roy U, Garg S, Ghosh S, Pathak S, Kolthur-Seetharam U. Sirt1 and miR-9 expression is regulated during glucose-stimulated insulin secretion in pancreatic beta-islets. FEBS J. 278(7), 1167-1174 (2011
94. Lovis P, Gattesco S, Regazzi R. Regulation of the expression of components of the exocytotic machinery of insulinsecreting cells by microRNAs. Biol. Chem. 389(3), 305-312 (2008
95. Chhabra R, Dubey R, Saini N. Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Mol. Cancer 9, 232 (2010
96. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of e-box repressors. Proc. Natl Acad. Sci. USA. 104(9), 3432-3437 (2007
97. Li R, Chung AC, Yu X, Lan HY. MicroRNAs in diabetic kidney disease. Int. J. Endocrinol. 2014, 593956 (2014
98. Prabu P, Rome S, Sathishkumar C, et al. Circulating miRNAs of 'Asian Indian phenotype' identified in subjects with impaired glucose tolerance and patients with Type 2 diabetes. PLoS ONE. 10(5), e0128372 (2015
99. Melkman-Zehavi T, Oren R, Kredo-Russo S, et al. MiRNAs control insulin content in pancreatic beta-cells via downregulation of transcriptional repressors. EMBO J. 30(5), 835-845 (2011
100. Zhou J, Meng Y, Tian S, et al. Comparative microRNA expression profiles of Cynomolgus monkeys, rat, and human reveal that miR-182 is involved in T2D pathogenic processes. J. Diabetes Res. 2014, 760397 (2014
101. Zhao X, Mohan R, Ozcan S, Tang X. MicroRNA-30d induces insulin transcription factor MafA and insulin production by targeting mitogen-Activated protein 4 kinase 4 (map4k4) in pancreatic beta-cells. J. Biol. Chem. 287(37), 31155-31164 (2012
102. Karolina DS, Tavintharan S, Armugam A, et al. Circulating miRNA profiles in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 97(12), E2271-E2276 (2012
103. Herrera BM, Lockstone HE, Taylor JM, et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of Type 2 diabetes. Diabetologia. 53(6), 1099-1109 (2010
104. Cai J, Wu J, Zhang H, et al. MiR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res. 73(2), 756-766 (2013
105. Chen BZ, Yu SL, Singh S, et al. Identification of microRNAs expressed highly in pancreatic islet-like cell clusters differentiated from human embryonic stem cells. Cell Biol. Int. 35(1), 29-37 (2011
106. Antoniou A, Mastroyiannopoulos NP, Uney JB, Phylactou LA. MiR-186 inhibits muscle cell differentiation through myogenin regulation. J. Biol. Chem. 289(7), 3923-3935 (2014
107. O'connell RM, Rao DS, Baltimore D. MicroRNA regulation of inflammatory responses. Annu. Rev. Immunol. 30, 295-312 (2012
108. Corral-Fernandez NE, Salgado-Bustamante M, Martinez-Leija ME, et al. Dysregulated miR-155 expression in peripheral blood mononuclear cells from patients with Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes. 121(6), 347-353 (2013
109. Kornfeld JW, Baitzel C, Konner AC, et al. Obesity-induced Overexpression of miR-802 Impairs Glucose Metabolism Through Silencing of Hnf1b. Nature. 494(7435), 111-115 (2013
110. Floris I, Descamps B, Vardeu A, et al. Gestational diabetes mellitus impairs fetal endothelial cell functions through a mechanism involving microRNA-101 and histone methyltransferase enhancer of zester homolog-2. Arterioscler. Thromb. Vasc. Biol. 35(3), 664-674 (2015
111. Sebastiani G, Grieco FA, Spagnuolo I, Galleri L, Cataldo D, Dotta F. Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab. Res. Rev. 27(8), 862-866 (2011
112. Caporali A, Meloni M, Vollenkle C, et al. Deregulation of microRNA-503 contributes to diabetes mellitusinduced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation. 123(3), 282-291 (2011
113. Pescador N, Perez-Barba M, Ibarra JM, Corbaton A, Martinez-Larrad MT, Serrano-Rios M. Serum circulating microRNA profiling for identification of potential Type 2 diabetes and obesity biomarkers. PLoS ONE. 8(10), e77251 (2013
114. Desai GS, Mathews ST. Saliva as a non-invasive diagnostic tool for inflammation and insulin-resistance. World J. Diabetes. 5(6), 730-738 (2014
115. Lee SY, Choi ME. Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatr. Nephrol. 30(7), 1063-1075 (2014
116. Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J. Cell Mol. Med. 18(3), 371-390 (2014